Overview

  • Product nameAnti-Plasminogen antibody [3C2]
    See all Plasminogen primary antibodies
  • Description
    Mouse monoclonal [3C2] to Plasminogen
  • SpecificityReacts with human plasminogen and plasmin molecules.
  • Tested applicationsSuitable for: ELISA, IHC-P, Flow Cyt, Othermore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Full length native protein (purified) (Human).

Properties

Applications

Our Abpromise guarantee covers the use of ab10178 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA Use at an assay dependent concentration.
AP Use at an assay dependent concentration.
IHC-P Use at an assay dependent concentration. Antigen retrieval is not essential but may optimise staining.
Flow Cyt Use 2µg for 106 cells. ab170190-Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.
Other Use at an assay dependent concentration.

Target

  • FunctionPlasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.
    Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.
  • Tissue specificityPresent in plasma and many other extracellular fluids. It is synthesized in the liver.
  • Involvement in diseaseDefects in PLG are a cause of susceptibility to thrombosis (THR) [MIM:188050]. It is a multifactorial disorder of hemostasis characterized by abnormal platelet aggregation in response to various agents and recurrent thrombi formation.
    Defects in PLG are the cause of plasminogen deficiency (PLGD) [MIM:217090]. PLGD is characterized by decreased serum plasminogen activity. Two forms of the disorder are distinguished: type 1 deficiency is additionally characterized by decreased plasminogen antigen levels and clinical symptoms, whereas type 2 deficiency, also known as dysplasminogenemia, is characterized by normal, or slightly reduced antigen levels, and absence of clinical manifestations. Plasminogen deficiency type 1 results in markedly impaired extracellular fibrinolysis and chronic mucosal pseudomembranous lesions due to subepithelial fibrin deposition and inflammation. The most common clinical manifestation of type 1 deficiency is ligneous conjunctivitis in which pseudomembranes formation on the palpebral surfaces of the eye progresses to white, yellow-white, or red thick masses with a wood-like consistency that replace the normal mucosa.
  • Sequence similaritiesBelongs to the peptidase S1 family. Plasminogen subfamily.
    Contains 5 kringle domains.
    Contains 1 PAN domain.
    Contains 1 peptidase S1 domain.
  • DomainKringle domains mediate interaction with CSPG4.
  • Post-translational
    modifications
    N-linked glycan contains N-acetyllactosamine and sialic acid. O-linked glycans consist of Gal-GalNAc disaccharide modified with up to 2 sialic acid residues (microheterogeneity).
    In the presence of the inhibitor, the activation involves only cleavage after Arg-580, yielding two chains held together by two disulfide bonds. In the absence of the inhibitor, the activation involves additionally the removal of the activation peptide.
  • Cellular localizationSecreted. Locates to the cell surface where it is proteolytically cleaved to produce the active plasmin. Interaction with HRG tethers it to the cell surface.
  • Information by UniProt
  • Database links
  • FormCleaved into the following 5 chains: 1.Plasmin heavy chain A2.Activation peptide3.Angiostatin4.Plasmin heavy chain A, short form5. Plasmin light chain B
  • Alternative names
    • Angiostatin antibody
    • DKFZp779M0222 antibody
    • Plasmin antibody
    • Plasmin heavy chain A antibody
    • Plasmin light chain B antibody
    • Plasminogen antibody
    • PLG antibody
    • PLMN_HUMAN antibody
    see all

Anti-Plasminogen antibody [3C2] images

  • ab10178 staining human brain tissue sections by IHC-P.  Sections were formaldehyde fixed and subjected to heat mediated antigen retrieval in EDTA prior to blocking in 10% serum for 20 hours at 37°C.  The primary antibody was diluted 1/200 and incubated with the sample for 18 hours at 37°C.  A biotinylated horse anti-mouse IgG antibody, diluted 1/500, was used as the secondary.

    See Abreview

  • Overlay histogram showing HepG2 cells stained with ab10178 (red line). The cells were fixed with 4% paraformaldehyde (10 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab10178, 2µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG1 [ICIGG1] (ab91353, 2µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed.

References for Anti-Plasminogen antibody [3C2] (ab10178)

This product has been referenced in:
  • Barker R  et al. Plasminogen and plasmin in Alzheimer's disease. Brain Res 1355:7-15 (2010). IHC-P ; Human . Read more (PubMed: 20709033) »
  • Datta S  et al. Ultrasound-enhanced thrombolysis using Definity as a cavitation nucleation agent. Ultrasound Med Biol 34:1421-33 (2008). IHC-Fr ; Human . Read more (PubMed: 18378380) »

See all 2 Publications for this product

Product Wall

Abcam guarantees this product to work in the species/application used in this Abreview.
Application Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections)
Sample Human Tissue sections (Brain)
Specification Brain
Fixative Formaldehyde
Antigen retrieval step Heat mediated - Buffer/Enzyme Used: EDTA
Permeabilization No
Blocking step Serum as blocking agent for 20 hour(s) and 0 minute(s) · Concentration: 10% · Temperature: 37°C
Username

Abcam user community

Verified customer

Submitted Jul 23 2008

Thank you very much for your email and patience. All the information that we have regarding these antibodies is located on the online datasheets. At this time, we don't have any information concerning the epitopes. For ELISA, ab10176 can be used as con...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"